Laboratoires Servier
↗Orléans, France
Servier is France's leading independent pharmaceutical company and the second-largest French pharmaceutical company by revenue. Founded in 1954 by Jacques Servier, the company has evolved from a nine-employee pharmaceutical production facility in Orléans, France to a global pharmaceutical group with over 22,000 employees operating in approximately 140 countries. Governed uniquely by a non-profit Foundation, Servier preserves its independence and long-term vision focused on therapeutic progress. The company is a world leader in cardiometabolism and venous diseases, with oncology as a new strategic pillar representing approximately 70% of R&D budget. In 2023/2024, Servier generated €5.9 billion in consolidated revenue with EBITDA of €1.313 billion (22.2% margin), demonstrating strong financial performance driven by robust international sales, particularly in oncology.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology biotech, Cardiometabolism, Immunology
SIZE & FINANCIALS
Employees:10000+
Revenue:$5-10B
Founded:1954
Ownership:private
Status:operating
PIPELINE
Stage:Preclinical through Commercial
Lead Drug Stage:Commercial (Voranigo/Vorasidenib approved Aug 2024)
Modalities:Small molecule, mAb, Targeted therapy, Oral therapeutics
Trial Phases:-
FDA Approvals:6
EMA Approvals:3
CORPORATE STRUCTURE
Subsidiaries:Servier Pharmaceuticals (USA), Biogaran (generics - under sale negotiation to BC Partners), Symphogen (antibody platform), Nihon Servier (Japan), Servier Brazil, Servier Russia, Servier Ireland, Multiple country-specific subsidiaries
Key Partnerships:IDEAYA Biosciences (darovasertib for uveal melanoma, 2025), Base4 Biotechnology (RNA-targeted small molecule therapeutics), Kaerus Bioscience (Fragile X syndrome KER-0193), CStone Pharmaceuticals (TIBSOVO rights in Greater China and Singapore, 2023), BC Partners (exclusive negotiations for Biogaran sale)
COMPETITION
Position:Leader
Competitors:Roche, Novartis, Eli Lilly, Johnson & Johnson, Pfizer, AstraZeneca, Merck, Novo Nordisk +2 more
LEADERSHIP
Key Executives:
Olivier Laureau - President and CEO of Servier Group
David K. Lee - Chief Executive Officer, Servier Pharmaceuticals (USA); Executive Vice President, U.S. Operations
Charlotte Marmousez-Tartar - Executive Vice President, Corporate Strategy & Transformation
Hani Friedman Bouganim - Executive Vice President, Manufacturing, Quality and Supply Chain
Matthias Staehelin - Chair, Supervisory Board
Steven Baert - Member, Supervisory Board
Scientific Founders:Jacques Servier (Founder, 1954)
Board Members:Matthias Staehelin (Chair), Steven Baert, Jean-Christophe Tellier, 7 additional independent supervisory board members (names not fully disclosed in available sources)
LINKS
Website:servier.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Laboratoires Servier. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.